collongues nicolas

Professor of Therapeutic-Neurology
@CHRUStrasbourg #INSERMU1119 Neutoprotective drugs in multiple sclerosis #NOMADMUS

[Neurology Journal @GreenJournal]

Study findings identify CD138 as a specific CSF biomarker for multiple sclerosis: https://t.co/xrDg6r9FCV

#NeuroTwitter #MS

[Matteo Gastaldi @MGastaldi85]

Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: the importance of intrathecal MOG-IgG synthesis https://t.co/uIk9E2JTuL
Check out our new study on MOG IgG intrathecal synthesis!
Congrats to @jacksax13 on his first @JNNP_BMJ paper

[ECTRIMS @ECTRIMS]

🧠 A new study found that cortical remyelination prevents atrophy and long-term disability in individuals at early stages of #MS and with limited cortical myelin loss. Discover new MS research findings in our latest Bulletin ➡️ https://t.co/P9TBQ9T3Ni

[France Sclérose En Plaques @France_SEP]

France Sclérose en plaques, c'est une #communauté🙋‍♀️🙋🙋‍♂️ engagée dans la lutte contre cette maladie.

Notre souhait est simple : unir 🫶 tous ceux qui luttent contre la #scléroseenplaques pour que nous puissions vaincre 🥊 cette maladie ensemble.

@FloDeygas

[Sara Mariotto @SaraMariottoMD]

Very successful MEDEN meeting, great to see many colleagues, such a stimulating networking! congrats @CartaSra 🤩🤩

[Georgina Arrambide @GeoArrambide]

And so MEDEN 2024 comes to a closure. See you next year in Lyon! @marignierro #NMOSD #MOGAD

[The Sumaira Foundation @TheSumairaFDN]

🇫🇷 C'est le dernier jour du mois #MOGAD

Découvrez MOGAD et l'importance de la participation des patients aux essais cliniques présenté par le Prof. Romain Marignier (@marignierro)

https://t.co/59AetOuPON

[Romain Marignier @marignierro]

Very nice discussion between Dr Justin Abbatemarco @JRAbbatemarco and Dr Geraldine Androdias from @CHUdeLyon on the Impact of Immune Checkpoint Inhibitors in MS Course
| Neurology® Podcast https://t.co/0tUjFMZkSE

[Journal of Neurology, Neurosurgery and Psychiatry @JNNP_BMJ]

Interesting findings on MOGAD. This paper shows non-P42 MOG-IgG as the first diagnostic predictor of a relapsing course.

Read more here 👇 🔎
https://t.co/ooWuC1Pa4b

@Ganesha_Li @darshi_r @Benjamin_Trewin @RussellCDale @marignierro @MasturaMonif @anneke_vdw et al

[Stanislas Demuth @DemuthStanislas]

Let's review the current panel of disease modifying treatments in #NMOSD with @CollonguesN ! #biotherapy #NOMADMUS

https://t.co/Rxcsi2FLQE

[MSJ @MSJ_Research]

In people with #MultipleSclerosis and EDSS above 6.5, respiratory disorders are common (73% - mostly diaphragm dysfunction) and could be addressed with instrumental interventions.

Cross-sectional study from @HopPitieSalpe @Sorbonne_Univ_ @Inserm ▶️ https://t.co/uO4QyY9xbO

[Neurology Journal @GreenJournal]

This study of a large, real-world cohort of rituximab-treated people with #MS found higher cumulative rituximab doses increased the risk of infections, even though most patients had normal IgG levels both at rituximab initiation and at last follow-up. https://t.co/XVcPPtAo9A

[nature @Nature]

After decades of slow progress, therapeutic vaccines that direct the immune system to attack tumours could soon become a fixture of cancer treatment https://t.co/ZJZ35mXl9T

[Sylvie Retailleau @sretailleau]

Voici une première mondiale.

Ces images de cerveau humain ont été produites au @CEAParisSaclay par #Iseult, l’IRM le plus puissant au monde.

Plus de 20 ans de recherche, une immense fierté et une révolution technologique qui ouvre des perspectives inouïes pour notre santé.

[Dr. Brandon Beaber @Brandon_Beaber]

Higher cumulative dose of rituximab for multiple sclerosis increases the risk of infections even if immunoglobins are normal.

[DrJE-Salem @DrJESalem]

Off press👇Last decade evolution of immune checkpoint inhibitors toxicities reported worldwide with evolution of risk factors, and outcomes. Myotoxicities (myocarditis, myositis mimicking myasthenia gravis) are strinkingly overlapping.
@CardioOncology https://t.co/wMsdt1R9kn

[Neurology Journal @GreenJournal]

According to this study, AQP4-Ab+ neuromyelitis optica spectrum disorder (#NMOSD) is associated with increased mortality and shorter life expectancy compared with that in the general population: https://t.co/TlQ3MsvkNU

#NeuroTwitter

[Gardien des poisons @Ordoscopie]

⚠️ Les effets indésirables associés aux Inhibiteurs de la Pompe à Protons (IPP).

https://t.co/Tu4RWiUXc2

[Journal of Neurology, Neurosurgery and Psychiatry @JNNP_BMJ]

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

https://t.co/XwUVFl1O79 @foongahh

[Neurology Journal @GreenJournal]

This study provides Class II evidence that evobrutinib reduces the volume of slowly expanding lesions assessed on MRI comparing baseline with week 48, in patients with relapsing multiple sclerosis: https://t.co/3nU8EwGVZZ

#NeuroTwitter #MS